Related Experiment Video
Updated: Jul 6, 2025
11:12
Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
Published on: August 1, 2018
8.0K
FEATURES OF COL1A1 EXPRESSION IN BREAST CANCER TISSUE OF YOUNG PATIENTS
V Chekhun1, O Mushii1, T Zadvornyi1
1R.E. Kavetsky Institute of Experimental Pathology, Oncology, and Radiobiology, National Academy of Sciences of Ukraine, Kyiv, Ukraine..
Experimental Oncology
|January 8, 2024
Summary
Collagen type 1 alpha 1 (COL1A1) gene expression is elevated in breast cancer (BCa) tissue and linked to tumor characteristics. Low COL1A1 protein levels in young BCa patients correlate with reduced survival, suggesting its potential as a prognostic marker.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Increasing incidence of breast cancer (BCa) in young women.
- The role of collagen in the tumor microenvironment and its association with BCa patient age and survival remains unclear.
Purpose of the Study:
- To investigate the relationship between COL1A1 gene expression (mRNA and protein) and clinicopathological features and survival rates in BCa patients across different age groups.
Main Methods:
- Analysis of COL1A1 mRNA and protein expression in 50 BCa patients using real-time PCR and immunohistochemistry.
- Bioinformatic analysis utilizing UALCAN and Kaplan-Meier Plotter databases.
- Correlation with clinicopathological data and survival outcomes.
Main Results:
- COL1A1 mRNA levels were significantly higher (6.0-fold) in BCa tissue compared to normal tissue.
- COL1A1 expression correlated with molecular subtypes and receptor status (ER, PR).
- Low COL1A1 protein expression was associated with lower relapse-free survival and decreased in aggressive BCa subtypes (T3, low differentiation, basal subtype) in young patients.
Conclusions:
- COL1A1 expression is linked to BCa aggressiveness, including tumor size, differentiation, molecular subtype, and receptor status.
- COL1A1 may serve as a predictive marker for BCa aggressiveness and recurrence-free survival in young patients.
